Paul Wallace Email & Phone Number

Whittlesford, Cambridge, Gb

Constructive Bio is a spin-out from the MRC Laboratory of Molecular Biology. The Company's technologies allow for the synthesis and recoding of entire genomes, enabling the design and production of entirely novel and improved biomolecules with unprecedented functionalities. Investors include Ahren Innovation Capital, Amadeus Capital Partners, Fine Structure Ventures, General Inception, ND Capital, OMX Ventures and Paladin Capital Group. 2024 winner of the Cambridge Independent Science and Technology Award for Start-up of the Year.

Cambridge, Cambridgeshire, Gb

University of Cambridge, Cavendish Laboratory spin-out that is using novel materials physics to develop micro-scale cell carriers for cell-based assays: turning adherent cells into liquid reagents; for miniaturization and cell multiplexing. 2024 winner of the SLAS Ignite Award for most innovative laboratory automation start-up in Europe. 2023 winner of the Business Weekly Pathfinder Award.

Cambridge, Cambs, Gb

Private pharmaceutical company. Targeting deubiquitylating enzymes to treat neurodegenerative disease, rare mitochondrial diseases, fibrosis, inflammation and cancers. Raised $125M venture capital from institutional and corporate investors. Strategic partnerships with AbbVie and Pfizer.

Huddinge, Se

Publicly listed pharmaceutical company. Head of business development during period when company took two drugs from research to launch (incl. HCV protease inhibitor Olysio®; $2B in first year with partner J&J) and transitioned from an early-stage R&D company into a profitable company with commercial sales. Executed 25 partnerships, the majority with major pharma.

Huddinge, Se

Public company, listed on LSE. Vaccines and protease inhibitor drugs. Trade sale to Sanofi-Aventis.

Private company. Antibody engineering and therapeutics. Trade sale to Merck KGaA.

Private company. Recombinant antibody therapeutics.Principal inventor of two humanised antibodies in late-stage clinical development for cancer indications: farletuzumab (phase III) and ontuxizumab (phase II).

Cambridge, England, Gb

Biochemistry and molecular biology. Cellular targeting and processing of proteins.

Ph.D., Biochemistry And Molecular Biology

B.Sc., First Class, Biochemistry